Mode
Text Size
Log in / Sign up

Sex hormone traits linked to Alzheimer's risk in sex-specific Mendelian randomization studyWomen and men face different Alzheimer's risks linked to specific hormones

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider sex-specific hormone pathways when assessing Alzheimer's risk, as testosterone and SHBG show protective associations.

This cohort study used Mendelian randomization to investigate causal relationships between sex hormone-related traits and Alzheimer's disease (AD) risk. The analysis included women and men, examining traits such as testosterone, SHBG, age at menarche, menopause, voice breaking, and estradiol levels.

Main results showed that bioavailable testosterone in women was associated with lower AD risk (OR: 0.88; 95%-CI: 0.82-0.96). Similarly, SHBG levels in men were associated with lower AD risk (OR: 0.86; 95%-CI: 0.77-0.96). However, estradiol-related traits showed no causal effect on AD risk.

The study identified 12 high-confidence pleiotropic loci, of which 9 showed stronger AD effect sizes in women (3 in men) and 8 were novel. Enrichment of AD with testosterone, SHBG, and age-at-menarche traits was observed in women.

No safety or tolerability data were reported as this was a genetic association study. Key limitations include that little remains known about the causal impact and relation to sex-biased genetic risk for AD.

These findings provide potential targets for sex-informed AD risk stratification and prevention strategies, though causal effects of estradiol-related traits were not supported.

Imagine waking up one morning and forgetting why you walked into a room. For millions of people, this is a terrifying reality. It is the early sign of Alzheimer's disease. This condition steals memories, changes personalities, and makes daily life incredibly hard.

Doctors have studied this disease for decades. They know it affects more women than men. But why? Is it just because women live longer? Or is there something deeper happening inside the body?

The Hidden Biological Difference

For a long time, scientists thought sex hormones were just background noise. They assumed estrogen and testosterone simply changed as we aged. But new data suggests these chemicals are actually key players. They might be the reason why the disease hits one group harder than another.

Think of your genes as a library of instructions. Usually, everyone has the same books. But sometimes, the way you read those books changes based on your biology. This research found that your hormones change how your genes work in the brain.

A New Way To Look At Risk

Old thinking said all hormones were bad or all were good. That was too simple. The truth is more complex. Some hormones act like a shield for one gender but not the other.

But here is the twist: the shield works differently for women and men. The study looked at many different hormones. It checked levels of testosterone, a protein called SHBG, and others. It compared how these levels linked to brain health in thousands of people.

How The Body Uses These Chemicals

To understand this, imagine a factory floor. Your genes are the machines. Hormones are the managers telling the machines what to do. In this new study, researchers found specific managers that stop damage in the brain.

One manager is testosterone. In women, higher levels of this hormone seem to tell the brain to repair itself better. Another manager is SHBG. In men, higher levels of this protein also tell the brain to stay healthy.

Scientists used a massive amount of data to find these links. They looked at people from several large health groups. They checked DNA from thousands of men and women. They wanted to see if certain hormone levels caused lower risk of Alzheimer's.

The results were clear. Women with higher bioavailable testosterone had a lower risk of developing the disease. Men with higher SHBG levels also had a lower risk. The numbers showed a strong connection. It was not just a coincidence.

But there is a catch.

These findings do not mean you should take hormone pills to prevent Alzheimer's. The study looked at natural levels in the body. It did not test giving extra hormones to people. The goal was to understand the biology, not to create a new drug immediately.

This research changes how doctors might think about risk. If a woman has low testosterone naturally, she might be at higher risk. If a man has low SHBG, he might need extra attention. Doctors could use these numbers to spot who needs help sooner.

It also means treatments might need to be different for men and women. A drug that works for men might not work for women if it ignores these hormonal differences. Science is moving toward personalized care.

This study is a major step forward. It names specific genes that drive these risks. It shows that biology is not one size fits all. However, we are still in the early stages.

More research is needed to turn these findings into real treatments. Scientists must test if boosting these hormones helps people in the lab and in clinics. It will take time to get approval for any new medicines.

For now, the message is simple. Know your biology. Talk to your doctor about your family history. Understand that your hormones play a big role in your brain health. This knowledge gives you power. It helps you ask the right questions. It helps you stay informed as science moves forward.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Alzheimer's disease (AD) exhibits marked sex differences. While sex hormone levels across the lifespan likely contribute to this, little remains known about their causal impact and their relation to sex-biased genetic risk for AD. We therefore sought to identify potential shared genetic architectures, as well as causal genes and relationships, between sex hormone-related traits and AD risk. Methods: Large-scale AD sex-stratified genome-wide association study (GWAS) results were available from case-control, proxy-based, and population-based cohorts, including the Alzheimer's Disease Genetics Consortium, Alzheimer's Disease Sequencing Project, UK Biobank, and FinnGen. Sex hormone-related trait GWAS were available for age at menarche, menopause, and voice breaking, as well as testosterone, sex hormone-binding globulin (SHBG), progesterone, follicle stimulating hormone, luteinizing hormone, and estradiol levels. Cross-trait conjunctional analyses were conducted to identify pleiotropic overlap between sex-hormone traits and AD, followed by prioritization of candidate causal sex-biased AD genes through quantitative trait locus genetic colocalization analyses. The potential regulatory impact of sex hormones on these genes was assessed through transcription factor motif analyses. Finally, sex-stratified mendelian randomization analyses were used to infer causal effects of sex hormones on AD risk. Results: Genome-wide pleiotropy analyses demonstrated enrichment of AD with testosterone, SHBG, and age-at-menarche traits in women. We identified 12 high-confidence pleiotropic loci, 9 of which showed stronger AD effect sizes in women (3 in men) and 8 that were novel. Genes at these loci were often causally implicated in brain tissues and enriched for promoter-associated androgen receptor transcription factor binding motifs. Mendelian randomization indicated higher bioavailable testosterone in women (OR:0.88; 95%-CI:0.82-0.96) and higher SHBG levels in men (OR:0.86; 95%-CI:0.77-0.96) were associated with lower AD risk. Conclusions: Our findings reveal sex-specific shared genetic architectures between AD and sex hormone-related traits and nominate related genes that may drive sex-biases in AD risk. Several of the implicated female-biased genes are relevant to phosphatidylinositol and lipid metabolism, including Fatty Acid Desaturase 2 (FADS2). While we observed no causal effect of estradiol-related traits on AD risk, the protective effects of bioavailable testosterone in women and SHBG in men provide targets for sex-informed AD risk stratification and prevention strategies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.